4 9 3 l e t t e r S Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor characterized by rapid and uniform patient demise 1 . A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors and results in a lysine-to-methionine substitution (H3K27M) 2, 3 . Expression of this histone mutant is accompanied by a reduction in the levels of polycomb repressive complex 2 (PRC2)-mediated H3K27 trimethylation (H3K27me3), and this is hypothesized to be a driving event of DIPG oncogenesis 4,5 . Despite a major loss of H3K27me3, PRC2 activity is still detected in DIPG cells positive for H3K27M 6, 7 . To investigate the functional roles of H3K27M and PRC2 in DIPG pathogenesis, we profiled the epigenome of H3K27M-mutant DIPG cells and found that H3K27M associates with increased H3K27 acetylation (H3K27ac). In accordance with previous biochemical data 5 , the majority of the heterotypic H3K27M-K27ac nucleosomes colocalize with bromodomain proteins at the loci of actively transcribed genes, whereas PRC2 is excluded from these regions; this suggests that H3K27M does not sequester PRC2 on chromatin. Residual PRC2 activity is required to maintain DIPG proliferative potential, by repressing neuronal differentiation and function. Finally, to examine the therapeutic potential of blocking the recruitment of bromodomain proteins by heterotypic H3K27M-K27ac nucleosomes in DIPG cells, we performed treatments in vivo with BET bromodomain inhibitors and demonstrate that they efficiently inhibit tumor progression, thus identifying this class of compounds as potential therapeutics in DIPG.
l e t t e r S Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor characterized by rapid and uniform patient demise 1 . A heterozygous point mutation of histone H3 occurs in more than 80% of these tumors and results in a lysine-to-methionine substitution (H3K27M) 2, 3 . Expression of this histone mutant is accompanied by a reduction in the levels of polycomb repressive complex 2 (PRC2)-mediated H3K27 trimethylation (H3K27me3), and this is hypothesized to be a driving event of DIPG oncogenesis 4, 5 . Despite a major loss of H3K27me3, PRC2 activity is still detected in DIPG cells positive for H3K27M 6, 7 . To investigate the functional roles of H3K27M and PRC2 in DIPG pathogenesis, we profiled the epigenome of H3K27M-mutant DIPG cells and found that H3K27M associates with increased H3K27 acetylation (H3K27ac). In accordance with previous biochemical data 5 , the majority of the heterotypic H3K27M-K27ac nucleosomes colocalize with bromodomain proteins at the loci of actively transcribed genes, whereas PRC2 is excluded from these regions; this suggests that H3K27M does not sequester PRC2 on chromatin. Residual PRC2 activity is required to maintain DIPG proliferative potential, by repressing neuronal differentiation and function. Finally, to examine the therapeutic potential of blocking the recruitment of bromodomain proteins by heterotypic H3K27M-K27ac nucleosomes in DIPG cells, we performed treatments in vivo with BET bromodomain inhibitors and demonstrate that they efficiently inhibit tumor progression, thus identifying this class of compounds as potential therapeutics in DIPG.
To advance understanding of the oncogenic molecular function of the H3K27M in oncogenesis, we mapped genome-wide occupancy of the mutant histone in DIPG cell lines by chromatin immunoprecipitation (ChIP)-seq, using an antibody directed against H3K27M (Supplementary Fig. 1 ). To confirm the specificity of the H3K27M antibody, we expressed wild-type or H3K27M-mutant histone at equivalent levels in HCT116 cells, a human colorectal tumor cell line ( Supplementary Fig. 1a ) and performed ChIP-seq. ChIP-seq signal with the H3K27M antibody was detected exclusively in H3K27M-expressing cells, whereas no enrichment was observed in cells expressing the wild-type counterpart ( Supplementary Fig. 1b-d) . ChIP-seq results from SF8628 human DIPG cells-which contain a mutant H3F3A gene that encodes H3.3K27M 8 -reveal a genomewide distribution of H3.3K27M that is highly correlated with active transcription, as indicated by the colocalization of acetylated H3K27 (H3K27ac) and RNA polymerase II (RNA pol II) (Fig. 1a-c and Supplementary Fig. 2a,b) . Intriguingly, this observation is recapitulated in SU-DIPG-IV (hereafter called DIPG-IV) cells, a DIPG cell line carrying a point mutation in the HIST1H3B gene that results in the expression of H3.1K27M 9 , and results obtained in SF7761 cells, another H3F3A-mutant DIPG line 8 , provide further support ( Supplementary Figs. 3 and 4) .
As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac 4, 5 (Fig. 1d) . To directly demonstrate a functional link between the expression of H3K27M and H3K27ac accumulation, we used a doxycycline-inducible system and found that H3K27M induction of H3K27ac is a reversible process (Supplementary Fig. 5a ). H3K27M localizes to H3K27ac sites that are present in wild-type H3.3-expressing cells, but importantly, it can induce a marked increase of H3K27ac at regions that show only modest H3K27ac enrichment in control cells (Supplementary Fig. 5b,c) . These changes in H3K27ac are reversible and return to distributions that are almost indistinguishable from those present in control H3.3-expressing cells after terminating H3K27M transgene expression ( Supplementary Fig. 5b,c) . Importantly, H3K27ac is Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas the only substantially increased histone acetylation mark induced by H3K27M, as determined by mass spectrometry analysis (Supplementary Figs. 6 and 7 and Supplementary Table 1) . Thus, H3K27M expression directly increases the levels of H3K27ac at specific genomic regions.
The H3K27M histone mutant is suggested to have increased binding affinity for EZH2 (refs. 4,6,10) ; our previous biochemical purifications of mononucleosomes containing H3K27M, however, did not show any preferential enrichment for PRC2 subunits 5 . To determine whether PRC2 subunits colocalize with H3K27M in vivo on chromatin, we analyzed the genome-wide distributions of PRC2, H3K27me3 and H3K27M histone in DIPG cells. Strikingly, PRC2 subunits EZH2 and SUZ12, as well as their enzymatic product, H3K27me3, are largely excluded from chromatin on sites containing H3K27M ( Fig. 1e,f;  Supplementary Figs. 2 and 8) . Collectively, these results indicate that H3K27M is not involved in PRC2 recruitment or sequestration on chromatin in vivo, but on the contrary, suggest that PRC2 binding to chromatin is excluded by locus-specific formation of H3K27M-K27ac heterotypic nucleosomes.
H3K27M has been hypothesized to drive gliomagenesis through PRC2 catalytic inhibition 4 , suggesting that a lack of PRC2 function is an important contributing factor to the development of H3K27M tumors. However, our results indicate that both PRC2 and the product of its catalytic activity, H3K27me3, are present at thousands of loci in DIPG cells 6, 7 (Fig. 1e,f and Supplementary Fig. 8a-f) . To address whether residual PRC2 activity is required by H3K27M tumor cells, we used lentiviral short hairpin RNAs (shRNAs) to suppress the expression of the essential PRC2 subunits SUZ12 and EED 11 . The growth and colony-forming ability of SUZ12 or EED knockdown cells are greatly reduced relative to those of control cells (Fig. 2a,b Supplementary Fig. 18 ). (e) Representative UCSC genome-browser view of a region enriched for PRC2 components and lacking H3.3K27M and active chromatin marks. (f) Heat-map analysis of the 5,000 most highly H3K27me3-enriched genomic loci in SF8628 cells, ranked in descending order from top to bottom, plotted as described in b.
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To identify potential targets of PRC2 that might drive DIPG cell proliferation, we focused our attention on CDKN2A (also known as p16), a negative cell-cycle regulator and well-established target of PRC2 transcriptional repression 12 . SUZ12 or EED knockdown resulted in derepression of p16 expression in SF8628 cells, consistent with a role for CDKN2A as a PRC2 target in these cells. By contrast, DIPG-IV cells do not upregulate p16 expression upon PRC2 depletion (Supplementary Figs. 10a,b and 9d) , despite the anti-proliferative effects of SUZ12 and EED knockdown in these cells (Fig. 2a,b and Supplementary Figs. 9a-d and 10a,b) .
To further explore the role of PRC2 in DIPG proliferation, we employed a small-molecule catalytic inhibitor of EZH2 methyltransferase activity, EPZ-6438. In agreement with the SUZ12 and EED knockdown results, H3K27M-positive DIPG cells treated with EPZ-6438 show reduced proliferation as compared to vehicle-treated cells (Supplementary Fig. 10c ). DIPG-IV cells tolerate higher doses of EPZ-6438 than SF8628 cells (Supplementary Fig. 10c ), and this probably reflects lower effectiveness of the chemical inhibitor in DIPG-IV, because a common PRC2 target gene, cyclin D2 (CCND2) (Fig. 2c-f) , simply requires increased doses to achieve derepression levels similar to those in SF8628 cells (Supplementary Fig. 10d) . Notably, the extent of target derepression is correlated with decreased proliferation in these cells (Supplementary Fig. 10c,d ). As for EED and SUZ12 knockdown, EZH2 catalytic inhibition does not elicit p16 upregulation in DIPG-IV cells (Supplementary Fig. 10d ). In combination, our results indicate that PRC2 pro-proliferative activity in H3K27M tumor cells can act through p16-independent mechanisms, as has been demonstrated already in other models 13 .
To further investigate global PRC2 transcriptional regulation, we performed transcriptome analyses (RNA-sequencing) of SUZ12 shRNA and control-vector-transduced SF8628 and DIPG-IV cells. Our analysis revealed that genes highly occupied by PRC2 in SF8628 and DIPG-IV cells show a trend of derepression upon SUZ12 depletion (Fig. 2c) . As expected from our previous results, genomic regions bearing PRC2 at their transcription start site (TSS) are characterized by the presence of H3K27me3 (87% in SF8628 cells and 92% in DIPG-IV cells). Many PRC2 targets are shared between SF8628 and DIPG-IV cells (70% and 40%, respectively; Fig. 2d,e) , and are significantly derepressed upon SUZ12 knockdown as compared to non-PRC2 target genes (P < 1.5 × 10 −22 in SF8628 cells and P < 1.17 × 10 −22 in DIPG-IV cells; Fig. 2f,g) . Thus, the activation of these genes suggests that they could functionally inhibit DIPG proliferation. Importantly, gene ontology (GO) analysis of common genes supports their importance in mediating neuronal-lineage differentiation and establishing mature neuronal functions (Fig. 2h) .
Although still functionally active, PRC2 catalytic property toward H3K27M-containing nucleosomes is strongly inhibited 4 . Interestingly, upon loss of H3K27me3, these nucleosomes acquire H3K27ac, which results in the formation of H3K27M-K27ac heterotypic nucleosomes 4 ( Fig. 1d and Supplementary Fig. 5b,c) . These observations support the increased association of acetyl-binding bromodomain proteins to H3K27M-containing nucleosomes 5 , and they prompted us to investigate the role of these proteins in DIPG cells. Strikingly, bromodomain-containing protein 2 (BRD2) and BRD4 show highly significant overlap with H3K27M-occupied sites P < 0.01 (Fig. 3a-d and Supplementary Figs. 2 and 3a-d) . BRD2-or BRD4-and H3K27M-cooccupied loci represent 85% of all BRD2-and BRD4-positive regions in SF8628 cells (Fig. 3d) . H3K27M localizes to promoters, intragenic regions and at H3K4me1-positive intergenic regions ( Supplementary  Fig. 11a,b) . We also found that H3K27M occupancy at active enhancers (H3K4me1-and H3K27ac-positive regions) is asymmetric and characterized by high-density occupancy over a fraction of active enhancers that also show increased presence of BRD2 or BRD4 and active transcription marks ( Supplementary Fig. 11c,d) ; this suggests that H3K27M participates in the formation of super-enhancer-like elements purported to have a key role in cancer 14 .
The strong co-occupancy between BRD2 and BRD4 proteins and H3K27M-K27ac heterotypic nucleosomes suggests a potential role of BRD proteins in DIPG pathogenesis. To address this point, we treated SF8628 cells and DIPG-IV cells with JQ1, a well-known bromodomain and extra-terminal domain (BET) inhibitor 15 . Dose-response analysis revealed submicromolar inhibitory concentration 50% (IC 50 ) values in the H3K27M-mutant cell lines as compared to glioblastoma cells not harboring that mutation (Supplementary Fig. 12a ), and the growthinhibitory effect of single-dose JQ1 administration extended to 5 d after treatment ( Fig. 3e and Supplementary Fig. 12b,c) . This effect was fully recapitulated by treatment with another BET inhibitor ( Fig. 3e and Supplementary Fig. 12d) . Interestingly, the anti-proliferative effect of JQ1 was accompanied by a neuron-like morphological change ( Supplementary Fig. 12e ).
In accordance with the crucial function of bromodomain proteins in transcriptional elongation 16 , we performed RNA-seq analysis during a time-course treatment with JQ1. Although at any given time point we observed both downregulated and upregulated gene expression, data l e t t e r S interpolation on the overall time-course shows a prevalent shutdown of many actively transcribed genes upon JQ1 treatment ( Fig. 3f and Supplementary Fig. 13a) . Importantly, the genes transcriptionally modulated by JQ1 show H3K27M, active transcription marks and BRD2 or BRD4 occupancy around their promoters, which indicates that they are direct targets ( Supplementary Fig. 13b,c) . Among the transcriptionally upregulated genes were CDKN1A (also known as p21), a marker of cell-cycle arrest 17 , and TUBB3 (also known as TUJ1) and MAP2, both markers of differentiation in mature neurons 18 , which further supports the neuron-like morphology change observed upon JQ1 treatment ( Fig. 3g and Supplementary Fig. 13d,e) . CDKN2A is unaffected by JQ1 treatment, which additionally suggests that, in this case, the phenotype is independent of p16 transcriptional regulation ( Fig. 3g and Supplementary Fig. 13d ). Fluorescence-activated cell sorting (FACS) analyses also confirmed that the majority of JQ1-treated cells demonstrated upregulation of the mature neuron marker l e t t e r S TUBB3 (Supplementary Fig. 13f ). Interestingly, JQ1 treatment elicited a time-dependent decrease in the activating H3K27ac mark 19 , consistent with the observed trend in transcriptional downregulation ( Fig. 3f and Supplementary Fig. 13a,e) .
To better understand the direct molecular effectors of the phenotype induced by JQ1, we assessed transcription of MYC, a wellknown downstream target of JQ1 in many tumors 20 . Surprisingly, we found a modest but consistent increase of MYC transcripts in both the SF8628 and DIPG-IV cell lines upon JQ1 as compared to vehicle treatment, whereas its closest homolog, MYCN, is silenced by PRC2 in those cells (Supplementary Fig. 14a,b) . These results exclude the possibility that JQ1 induces growth arrest and upregulation of differentiation markers through canonical reduction in MYC transcription. Focusing on genes downregulated by JQ1 at an early time point (6 h), we performed GO analysis. Interestingly, both SF8628 and DIPG-IV cells share the top downregulated molecular functions rather than the upregulated ones. Among them emerged the GO term 'transcription-factor activity,' which suggests that JQ1 might affect an important transcriptional network in DIPG (Supplementary Fig.  15a,b) . Interestingly, one of the main downregulated transcripts is GLI2, a crucial downstream effector of the sonic hedgehog (SHH) pathway 21 , that is a BRD2 or BRD4 and H3K27M-K27ac heterotypic nucleosomes target (Supplementary Fig. 16a,b) . The SHH pathway is implicated in DIPG pathogenesis, given that the candidate DIPG cell of origin is proposed to be a SHH-responsive cell 9 . Moreover, the inhibition or activation of Hedgehog signaling negatively or positively, respectively, affects DIPG-neurosphere formation ability 9 . Interestingly, some genes previously reported to be preferentially expressed in H3.3K27M DIPG, when compared to H3 wild-type gliomas 6 , are targets of heterotypic nucleosomes and BRD2 and BRD4, as shown by the decrease in expression induced by JQ1 treatment (Supplementary Fig. 16c-e) .
To investigate JQ1 activity against K27M DIPG in vivo, we employed a xenograft mouse model of DIPG based on the injection of SF8628 cells into the brainstem of athymic mice 8 . Remarkably, mice treated with JQ1 for 10 d exhibited significantly reduced tumor sizes, as indicated by bioluminescence imaging, and prolonged animal survival as compared to vehicle-treated mice (Fig. 4a,b) . H&E staining and Ki67-a marker of cell proliferation 22 -staining of brainstem tumors from mice killed upon the completion of a 10-d treatment period confirmed a dramatic reduction of tumor burden as compared to controls (Fig. 4c) . Given that JQ1 treatment causes marked reduction of global H3K27ac levels in DIPG cells (Supplementary Fig. 13e ), we performed an immunohistochemistry analysis for H3K27ac on tumors coming from JQ1-treated and control mice as a surrogate marker for JQ1 target inhibition. This analysis revealed significantly lower H3K27ac levels in tumors coming from JQ1-treated mice as compared to controls, which thus reflects direct target inhibition in vivo (Supplementary Fig. 17a ). To further support our in vivo data, we used another BET inhibitor (I-BET151) to treat our xenograft DIPG model (Supplementary Fig. 17b ) and also tested JQ1 against H3.1K27M-DIPG-IV xenografts ( Supplementary Fig. 17c) ; both approaches showed substantial impairment of DIPG growth in vivo. Importantly, treatment with JQ1 strongly inhibits the proliferation of DIPG cells in vivo, as evidenced by reduced numbers of mitotic events in JQ1-treated tumors as compared to control treatment, without significantly altering apoptosis (Fig. 4d,e) . Furthermore, we were also able to demonstrate the induction of TUBB3 levels in JQ1-treated tumors as compared to control treatment (Fig. 4f) , thus providing in vivo support for our in vitro observation that JQ1 tumor-growth inhibition is accompanied by an upregulation of differentiation markers in DIPG cells. Finally, JQ1-treated DIPG xenograft mice show substantially improved survival even when compared to treatment with GSK-J4, a compound previously proposed as a candidate drug to treat DIPG (Supplementary Fig. 17d ). All together, our data provide strong support for the use of BET inhibitors as a promising therapeutic strategy in DIPG.
Here we provide the first characterization of the genome-wide deposition of the H3K27M mutant histone in human DIPG cells. Strikingly, H3K27M colocalizes with transcriptionally active chromatin regions, and it is largely excluded from regions that are occupied by PRC2 and H3K27me3. Moreover, H3K27M-containing nucleosomes are enriched for acetylated H3K27 (ref. 4) (Fig. 1d) , and, in agreement with our previous biochemical data 5 , heterotypic nucleosomes demonstrate high co-occupancy with bromodomain proteins (Fig.  3a-d) . In our DIPG cells, PRC2 is almost entirely confined to chromatin regions marked with H3K27me3, and this mark is mutually exclusive with H3K27ac (ref. 23) . Given the high overlap between H3K27M and H3K27ac binding regions, the possibility that H3K27M somehow co-occupies many chromatin regions with EZH2 or PRC2 is unlikely. Collectively, these results strongly indicate that H3K27M in DIPG cells does not seem to recruit or sequester EZH2 (or in general, PRC2), as other studies have suggested 4, 6, 7 . Rather, our data support a model in which H3K27M excludes PRC2 binding, which thus induces aberrant accumulation of H3K27ac at H3K27M-binding sites, consistent with PRC2 loss of function in other systems 24, 25 . PRC2 activity is redirected during the neuronal differentiation of mouse embryonic stem cells, which suggests that external signals shape PRC2 recruitment; this then might result in the repression of distinct gene sets at specific developmental stages 26 . Heterotypic H3K27M-K27ac nucleosomes might, on the one hand, create an impediment for PRC2 repressive activity at a critical subset of genes involved in the maintenance of an undifferentiated state; on the other hand, they might confine PRC2 to genes that should be activated during the differentiation process.
This, in cooperation with other genetic alterations characterizing DIPG (for example, TP53, PDGFRA, ACVR1, etc.), would increase cell proliferation potential and decrease differentiation ability-two events widely known to be hallmarks of cancer 27, 28 . Therefore, a logical conclusion from our data is the possibility that, although locusspecific reduction of PRC2 activity or binding by H3K27M could promote DIPG formation, the overall PRC2 function is essential for tumor maintenance. Abrogation of the anti-differentiation effect of H3K27M-K27ac heterotypic nucleosomes through the use of BET inhibitors such as JQ1 could conceivably provide the dual benefit of decreasing DIPG cell proliferation while also promoting terminal neuronal differentiation of the tumor cells. Recently, a comprehensive drug screening for promising agents for DIPG therapy identified histone deacetylase (HDAC) inhibitors as potentially suitable for DIPG treatment 29 . Interestingly, HDAC inhibitors can synergize with JQ1 in a mouse model of pancreatic cancer 30 and in a mouse model of lymphoma, in which they were suggested to induce similar transcriptional outcomes 31 ; these pave the ground for a combinatorial therapy in DIPG. In conclusion, our work provides important molecular insights about H3K27M function in DIPG oncogenesis, and identifies PRC2 and BET bromodomain proteins as potential therapeutic targets for this disease.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
l e t t e r S oNLINE METHoDS
Cell sources and propagation. Primary pediatric human glioma cell lines, SF8628, SF7761 and SU-DIPG-IV, pcGBM2, SF9402 and SF9427 cells were obtained from the University of California, San Francisco (UCSF), medical center and Stanford University, and in accordance with institutionally approved protocols at each institution. Establishment of SF8628 and SF7761 cell cultures, from surgical specimens, and tumor cell modification for expression of firefly luciferase, for in vivo bioluminescence imaging, have been described 8, 32, 33 . The SU-DIPG-IV cell line described previously 9 was adapted to the following growth conditions: DMEM 1× (Thermo Fisher), 10% serum (Corning), 1× glutamine (Life Technologies), 1× penicillin/streptomycin (Life Technologies), cells were grown in a CO 2 incubator (5% CO 2 ) at 37 °C. HEK293T and HCT116 cells were grown using the same conditions as SU-DIPG-IV. Cell images were taken using a Leica inverted microscope (DM IL) 40× objective and a QICAM fast 1394 camera (QImaging).
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) was performed by following previously described protocols [34] [35] [36] . ~5 × 10 7 cells for each immunoprecipitation were crosslinked using freshly prepared 1% formaldehyde in complete cell medium (described in 'Cell sources and propagation') for 10 min at room temperature (RT) and subsequently quenched with 0.125-M glycine for at least 5 min and then rinsed twice in PBS. Cells were gently scraped from the plates and centrifuged in a 15-ml tube (Falcon) at 1,350g for 5 min at 4 °C. Cells were resuspended in 10-ml of Buffer 1 (50-mM HEPES at pH = 7.5, 140-mM NaCl, 1-mM EDTA, 10% glycerol, 0.5% Igepal, 0.25% Triton X-100) for 10 min at 4 °C. They were then centrifuged at 1,350g for 5 min at 4 °C. Pellet was resuspended in 10 ml of Buffer 2 (10-mM Tris-HCl at pH = 8.0, 200-mM NaCl, 1-mM EDTA, 0.5-mM EGTA) at RT for 10 min, and then centrifuged at 1,350g for 5 min at 4 °C. Pellet was resuspended in 1 ml Buffer 3 (10-mM Tris-HCl at pH = 8.0, 1-mM EDTA, 0.1% SDS) and transferred to a milliTUBE (1 ml, Covaris) and sonicated using E220 focused-ultrasonicator (Covaris) using the following parameters: 20% duty cycle, 175 PIP, 200 cycles/burst, 1,500 s. 50 µl of chromatin were de-crosslinked by adding 200 µl of Elution Buffer (50-mM Tris-HCl at pH = 8.0, 10-mM EDTA, 1.0% SDS) for 1.5-2 h at 65 °C, and the DNA was extracted using a PRC purification kit (QIAGEN). DNA fragments were loaded in a 1% agarose gel and checked for their size (average range, 200-600 bp). The remaining sheared chromatin (~950 µl) was centrifuged at 20,000g for 15 min at 4 °C to remove cellular debris. 100 µl of 10 X ChIP dilution buffer (10% Triton x-100, 1-M NaCl, 1% Na-deoxycholate, 5% N-lauroylsarcosine) was added to sheared chromatin. 10 µl was saved as input, and the remaining was subsequently incubated with a specific antibody overnight at 4 °C on a nutator (for antibody list, refer to Supplementary Table 2) . The following day, 50 µl of protein A/G agarose beads (Santa Cruz biotech) were added and incubated for 3 h at 4 °C on a nutator. Beads were then pelleted by centrifugation at 2,500g for 1 min and washed with 1 ml of RIPA buffer (50-mM HEPES at pH = 7.5, 500-mM LiCl, 1-mM EDTA, 1.0% Igepal, 0.7% Na-deoxycholate). The washing procedure was repeated four times. An extra wash was finally performed with 1 ml of 50-mM NaCl in TE 1X. Inputs and beads were then resuspended in 200 µl of elution buffer for 30 min at 65 °C and then centrifuged for 2 min at 15,000g. The supernatant was transferred in new tubes and de-crosslinked overnight at 65 °C. The following day, DNA was extracted using a PCR purification kit (QIAGEN) in a final volume of 70 µl.
ChIP-seq library preparation. ChIP-sequencing libraries were prepared using the KAPA HTP Library Preparation Kit complemented with NEXTflex DNA Barcodes from Bioo Scientific. 10 ng of DNA was used as starting material for input and IP samples. Libraries were amplified using 13 cycles on the thermocycler. Postamplification libraries were size selected at 250-450 bp in length using Agencourt AMPure XP beads from Beckman Coulter. Libraries were validated using the Agilent High Sensitivity DNA Kit.
RNA extraction and RNA-seq library preparation. Cell pellets were generated after 6 or 7 d from antibiotic selection after shSUZ12, and after 2 d from antibiotic selection after shEED and relatively control vector infection. For JQ1-treated cells, pellets were generated at specific time points, as indicated in the figures. DMSO-treated cell pellets were collected at 48 h. Pellets were usually stored at −80 °C or processed immediately for RNA extraction. RNA was extracted using RNeasy Plus micro kit (QIAGEN). RNA-sequencing libraries were prepared using the Illumina TruSeq Stranded Total RNA Preparation Kit with Ribo-Depletion. Input RNA quality was validated using the Agilent RNA 6000 Nano Kit. 1 µg of total RNA was used as starting material. Libraries were validated using the Agilent DNA 1000 Kit.
Next-generation sequencing. ChIP-seq and RNA-seq libraries were singleread (SR) sequenced on the Illumina NextSeq 500 Sequencing System.
ChIP-seq analysis. ChIP-seq reads were trimmed from the 3′ end until the final base had a quality score > 30, using Trimmomatic 37 , and were aligned to the human genome (UCSC hg19, using Bowtie version 1.1.2) 38 . Only uniquely mapping reads with, at most, two mismatches over the entire length of the read were considered for further analysis. To generate the UCSC genome browser tracks, locations of the mapped ChIP-seq reads were extended to 150 bp to represent sequenced fragments, were normalized to total reads aligned (reads per million, r.p.m.), and were formatted as bigWig coverage plots. Peaks were called from the aligned reads using SICER version 1.1 (ref. 39) . SICER was run with a window size of 200, a fragment size of 150, an effective genome fraction of 0.8, a gap size of 600 and an FDR threshold of 1 ×10 −8 . In each case, peaks were determined relative to an input control. Genes and transcription start sites nearest to peaks were identified from Ensembl release 72. For large-scale analyses, r.p.m. numbers were summed for each 25-bp window tiling the 5-kb immediately upstream and downstream of the highest r.p.m. signal in a peak (or upstream and downstream of transcription start sites; Fig. 2c ). The r.p.m. values in each window were either plotted separately for each locus to generate heat maps (exported from R in a "cdt" table, which was plotted within Java TreeView 40 ) or averaged and plotted in R with the gplots package to create metaplots.
RNA-seq analysis. Total RNA-seq reads were trimmed from the 3′ end until the final base had a quality score > 30, using Trimmomatic 37 , and then aligned to the human genome (UCSC hg19, using Tophat version 2.1.0) 41 with gene annotations from Ensembl release 72, allowing only uniquely mapped reads. Raw read counts were normalized to r.p.m. per sample and then displayed in the UCSC genome browser as bigWig-formatted coverage tracks. Exonic reads were assigned to specific genes from Ensembl release 72 using htseq-count from the python package HTSeq-0.6.1 (ref. 42) . We used the R Bioconductor package edgeR, version 3.12.0 (ref. 43) , to fit the data to a negative binomial generalized log-linear model and estimate a dispersion parameter. We used an adjusted P value threshold of 0.01 to identify genes significantly differentially expressed in one experimental condition relative to another. In addition to finding differentially expressed genes for each time point individually (two replicates of JQ1-treated cells versus two replicates of DMSO-treated cells, repeated for each cell line), we also used edgeR to fit splines with different degrees of freedom to the time courses. We also identified those genes that fit a single-degree spline in the JQ1 but not DMSO time course, treating each cell line independently. All groups of differentially expressed genes were analyzed for functional enrichment for specific biological processes or molecular functions using the R Bioconductor package TopGO (Alexa A and Rahnenfuhrer J (2010)) using a background gene set from hg19 in Ensembl release 75.
Mononucleosome purification and immunoprecipitation. H3.3 wild-type and H3.3K27M containing mononucleosomes were purified from HEK293 TRex FLP-in cells, as previously described 5 . Briefly, cells were induced with 1.0 µg/ml doxycycline to express histone transgenes. Cells were harvested and lysed in Buffer A (10-mM HEPES, pH 7.9, 10-mM KCl, 1.5-mM MgCl 2 , 340-mM sucrose, 10% glycerol, 0.1% Triton X-100, 0.5-mM DTT, 0.5× Protease inhibitor, 10-mM sodium butyrate), and nuclei were isolated by centrifugation through a sucrose cushion (30% sucrose, 10-mM HEPES, pH 7.9, 1.5-mM MgCl2, 10-mM sodium butryate). Nuclei were digested using micrococcal nuclease (New England BioLabs, M0247S) in Buffer A containing 1-mM CaCl 2 for 15 min at 37 °C. MNase digestion was inhibited by the addition of 2-mM EGTA, 1-mM EDTA, 100-mM KCl and 0.05% Triton X-100. Cleared lysates were incubated with 100-µl anti-FLAG M2 agarose (Sigma-Aldrich, #A2220) for 2 h at 4 °C. Beads were washed with washing buffer (50-mM HEPES, pH 7.9, 100-mM KCl, 10% glycerol, 1-mM EDTA, 2-mM EGTA, 10-mM sodium butyrate, 0.05% Triton X-100), and proteins were eluted in 20-mM HEPES, pH 7.9, 100-mM NaCl, 10-mM sodium butyrate, 0.1 mg/ml 3× FLAG peptide (Sigma-Aldrich, #F4799).
Plasmid vectors and lentiviral infections. H3.3 wild-type and H3.3K27M cDNA full-length fused to a short sequence codifying six histidine residues were cloned into the pINDUCER lentiviral vector (Addgene plasmid #44012 (ref. 44 ) using gateway technology (Thermo Fisher). Lentiviral particle assembly and infection procedure were performed as previously described. HCT116 cells were transduced with H3.3-wild-type-and H3.3K27M-expressing lentiviral vectors. Neomycin (1 mg/ml) was added to select infected cells for 5 d. Transgene expression was induced for 4 d by adding doxycyline (200 ng/ml) every 2 d. For the experiment in Supplementary Figure 5 , doxycycline was initially added for 7 d and then withdrawn for 21 d. SF8628 and SU-DIPG-IV cells were transduced with SUZ12 shRNA, EED shRNA and control vectors, as previously described. Briefly, 1 × 10 6 cells were plated the day before the infection. The following day, 0.45-µl filtered medium enriched with viral particles was applied to the cells, and 10 µg/ml polybrene (Sigma-Aldrich) was added. After 6-8 h, cells were washed in PBS 1X, and fresh medium was applied overnight. The entire procedure was repeated the following day. After that, the cells were selected with 150-µg/ml hygromicin B (Invitrogen) for 3-4 d (SUZ12 shRNA and control) or with puromycin 2 µg/ml (EED shRNA and control).
Western blot. Cell pellets were generated after 6 or 7 d from antibiotic selection after shSUZ12, shEED and control vector infections, or after 7 or 8 d of treatment with EPZM-6438 or DMSO. For JQ1-treated cells, the pellets were generated at specific time points, as indicated in the figures. DMSO-treated cell pellets were collected at 48 h. Pellets were usually stored at −80 °C or processed immediately for protein extraction. Cell pellets were lysed in an appropriate volume (typically 5-7 times the pellet volume) of S300 buffer (20-mM TrisHCl at pH 7.6, 300-mM NaCl, 5% glycerol, 0.2% Igepal) supplemented with protease cocktail inhibitor (Roche) at 4 °C. Subsequently, the protein lysate was transferred to one or more milliTUBE (1 ml, Covaris) or microTUBE (100 µL, Covaris), according to the volume, and sonicated using E220 focused-ultrasonicator (Covaris) using following parameters: 20% duty cycle, 175 PIP, 200 cycles/burst, 300 s. The sonicated protein extracts were centrifuged at 20,000g for 15 min at 4 °C to remove cellular debris. Bradford total protein quantification was performed using Coomassie Plus (Thermo Fisher), and all the protein extract volumes were adjusted to the same concentration. 40-60 µg of total protein extracts were resolved in SDS-PAGE. Proteins were then transferred to a nitrocellulose membrane (Thermo Fisher) and blocked with Tween 0.1% TBS (T-TBS), 5% milk powder overnight at 4 °C. Blocked membranes were then incubated in primary antibody, diluted in blocking solution for 2h at RT (for antibodies, see Table 2 ), washed 3 times with T-TBS and incubated for 1h in secondary antibody diluted in blocking solution. Membranes were again washed 3 times with T-TBS, ECL (Millipore) was added to the membrane and the signal was detected on film (Central Infusion Alliance) or digitally acquired using ChemiDoc Touch imaging system (Biorad).
Growth curves. Growth curves were performed as previously described 13 . Briefly, 5 × 10 4 cells/well were plated in a six-well plate (Corning) for each day in triplicate. Every day, a single plate of cells was fixed using 4% formaldehyde diluted in PBS (Life Technologies) for 10 min at RT, washed with water twice and left to air dry overnight. At the end of the curve (5 d), all cells were stained using a 0.1% solution of crystal violet (Sigma-Aldrich) for 30 min at RT, washed four times in water and air dried overnight. Crystal violet was solubilized in 10% acetic acid (Fisher), and absorbance was measured at λ = 590 nm. For shRNA SUZ12 and EED experiments, cells were seeded after 5 or 6 d upon antibiotic selection after infection. JQ1 (Selleckchem), OTX015 (Selleckchem) and EPZM-6438 was resuspended in DMSO at 10 mM, and stock aliquots were kept at −20 °C. For growth-curve experiments with JQ1 and OTX015 treatment, the drug and the vehicle control (DMSO) were added once at the beginning of the experiment (day 1) to all the plates. For EPZM-6438 treatment, cells were pretreated for 7 d (fresh inhibitor was added every other day) and the treatment was continued (on the same schedule as pretreatment) for the entire growth-curve experiment.
Xenograft model. Details about mice and procedures used in this study were presented previously 8 . All protocols, described below, were approved by the Northwestern University Institutional Animal Care and Use Committee. For the in vivo therapy response analysis, ten mice were randomly assigned to vehicle (DMSO, n = 9) and JQ1 (n = 9) treatment groups, with JQ1 administration by intraperitoneal (i.p.) injection at 50 mg −1 kg −1 , with once daily administration for 10 d. An additional two mice, not included in the survival analysis, were killed 6 h after administration of final treatment, and the brains of these mice were resected and placed in 4% paraformaldehyde (PFA). To investigate the efficacy of JQ1 treatment against H3K27M mutant DIPG, 4 × 106 SU-DIPG-IV cells, in 0.4 ml of cell-culture media with matrigel (BD Bioscience) were injected into the right flank of mice. Mice were randomly assigned to vehicle (DMSO, n = 4) and JQ1 (n = 5) treatment groups, with JQ1 administration by i.p. injection at 50 mg/kg, with once daily administration for 10 d. All of these treatments were initiated on day 7 following tumor cell implantation. Tumor growth and responses to therapy were determined twice weekly by bioluminescence imaging. Bioluminescence measurements for each animal at each time point were normalized against corresponding readings obtained at the beginning of therapy. To investigate the efficacy of I-BET (I-BET-762, ApexBio) treatment against H3K27M mutant DIPG, 1 × 105 SF8628 cells in 1 µl Hanks' Balanced Salt Solution, without Ca 2+ and Mg 2+ , were slowly injected into the pontine tegmentum, as described above. Mice were randomly assigned to vehicle (OraPlus, n = 9) and I-BET (n = 5) treatment groups, with I-BET administration by oral gavage at 50 mg/kg, with once daily administration for 10 d. All of these treatments were initiated on day 48 following tumor cell implantation. GSKJ4-treatment protocol was described before 8 . Mice monitoring, tumor-growth imaging and quantification, survival plots and relative statistical analyses were performed as described in previous studies 8 . Two mice from the control group in Figure 4a died immediately after the end of the vehicle administration and were therefore excluded from the survival study. Four mice from the treatment group and one mouse from the vehicle group in the experiments presented respectively in Supplementary  Figure 17b ,c were killed for tumor-unrelated problems and therefore excluded from the study.
Histological analyses. Histologic scoring of apoptotic bodies and mitoses was performed on 4-µm-thick sections of PDX DIPG at 200×, cut from formalin-fixed, paraffin-embedded blocks and stained with H&E. Anti-KI67 and anti-H3K27ac were diluted in antibody diluent and applied to slides at RT for 1 h. The Dako EnVision+ System-HRP (DAB) for use with rabbit antibody was used as a visualization system (K4011, DAKO). TUNEL staining was performed using the ApopTag peroxidase in situ apoptosis detection kit (S7100, Millipore), according to the manufacturer's protocol. The intensity of the H3K27ac in each cell from JQ1-and control-treated PDX tumor slides (n = 50 each group) was measured using ImageJ.
Slide scan. Coronal sections of mouse brainstems were stained with H&E and KI67 and then were digitized via a Hamamatsu Nanozoomer 2.0 HT Digital Pathology Slide Scanner (Hamamatsu, Skokie, IL). Images were processed using Adobe Photoshop CC (San Jose, CA). Double immunofluorescence on tissue sections. Serial sections of 4 µm were cut from paraffin blocks of PDX tissue samples and used for immunohistochemical and double-immunofluorescence assays. Slides were placed at 60 °C for 1 h; deparaffinized through three changes of xylene; hydrated to water by two changes of 100% ethanol, two changes of 95% ethanol, one of 80% ethanol, one of 70% ethanol and two changes of distilled water. Antigen retrieval was performed using 1X Dako Target Retrieval Solution pH 6 (cat #S1699, Carpinteria, CA). The slides were incubated in Biocare Medical Decloaking Chamber at 110 °C for 5 min; rinsed in distilled water two times and in PBS for 5 min. If the staining was performed on mouse tissue, an additional mouse
